C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · IEX Real-Time Price · USD
6.87
+0.04 (0.59%)
At close: Apr 17, 2024, 4:00 PM
6.89
+0.02 (0.29%)
After-hours: Apr 17, 2024, 6:10 PM EDT
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 8.86, with a low estimate of 2.00 and a high estimate of 16. The average target predicts an increase of 28.97% from the current stock price of 6.87.
Analyst Consensus: Buy
* Price targets were last updated on Feb 26, 2024.
Analyst Ratings
The average analyst rating for CCCC stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 1 | 1 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Morgan Stanley | Morgan Stanley | Hold Maintains $1 → $8 | Hold | Maintains | $1 → $8 | +16.45% | Feb 26, 2024 |
Stifel | Stifel | Strong Buy Reiterates $12 → $13 | Strong Buy | Reiterates | $12 → $13 | +89.23% | Feb 23, 2024 |
JP Morgan | JP Morgan | Sell → Hold Upgrades $6 | Sell → Hold | Upgrades | $6 | -12.66% | Jan 29, 2024 |
Stifel | Stifel | Hold → Strong Buy Upgrades $2 → $12 | Hold → Strong Buy | Upgrades | $2 → $12 | +74.67% | Dec 13, 2023 |
Morgan Stanley | Morgan Stanley | Sell → Hold Upgrades $3 → $1 | Sell → Hold | Upgrades | $3 → $1 | -85.44% | Nov 6, 2023 |
Financial Forecast
Revenue This Year
27.37M
from 20.76M
Increased by 31.87%
Revenue Next Year
21.88M
from 27.37M
Decreased by -20.06%
EPS This Year
-1.89
from -2.67
EPS Next Year
-1.96
from -1.89
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 48.3M | 52.5M | 495.5M | 4.7B | 13.5B |
Avg | 27.4M | 21.9M | 155.9M | 935.6M | 2.7B |
Low | n/a | n/a | n/a | n/a | 13.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 132.7% | 91.8% | 2,164.6% | 2,928.4% | 1,344.2% |
Avg | 31.9% | -20.1% | 612.3% | 500.3% | 192.0% |
Low | - | - | - | - | -98.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.13 | -0.85 | -0.36 | -1.65 | -1.37 |
Avg | -1.89 | -1.96 | -1.26 | -2.89 | -2.13 |
Low | -2.47 | -2.95 | -1.80 | -4.01 | -2.81 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.